Skip to content

Trial Summary

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.



ACTRN/NCT /ethics:


Scientific title:

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Sponsor / Cooperative group:

Genentech, Inc.

Trial & Patient Characteristics

Cancer TypeNon-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumours
Trial TypeInterventional
PhasePhase I
Age Range18 Years and older  
Tumour Stream -
Cancer Stage-
Anticipated Start Date2020-07-29
Anticipated End Date2024-11-30

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlison Richards
Phone08 8206 4835
Principal InvestigatorShawgi Sukumaran
Recruitment StatusRecruiting